Lisa Fund Grant: Now Accepting Applications

Postdoctoral or clinical research fellows planning to do translational or clinical research that focuses on novel THERAPEUTIC APPROACHES for late-stage metastatic colorectal cancer may now apply for The Fight Colorectal Cancer-AACR research grant. This grant is distributed through Fight Colorectal Cancer’s Lisa Fund.…  Read More

FDA Approves Avastin for New Second-Line Use

For patients with metastatic colorectal cancer, the Food and Drug Administration (FDA) has approved a new use of Avastin® (bevacizumab): It can be continued as part of ‘second-line’ combination therapy, even if it was used in first-line therapy. When stage…  Read More

New Cancer Drug Zaltrap Discounted by 50%

By Curt Pesman and Mary Miller In an unusual move, sanofi pharmaceutical company has instituted a 50 percent discount, effective immediately, on its latest cancer drug Zaltrap.  The reason for the sharp price drop, company officials said, was “market resistance” to…  Read More

Circulating Tumor Cells And CEA Levels Help Predict Survival in Metastatic CRC

Circulating tumor cells (rare cells from a cancerous tumor that appear in the bloodstream) can help predict how a person with metastatic colorectal cancer (mCRC) might do over time. A study published in the October 2012 Annals of Oncology compared…  Read More

Memorial Sloan-Kettering Will Not Offer Zaltrap

Memorial Sloan-Kettering Cancer Center made a very public announcement—and explanation—today in a New York Times op-ed about why they will not offer the new drug Zaltrap® (ziv-aflibercept) to its metastatic colorectal cancer patients. The authors, all world-renowned cancer specialists at the…  Read More

FDA Approves Regorafenib for Metastatic CRC

  The FDA today approved the use of the drug regorafenib (brand name Stivarga) for patients whose metastatic colorectal cancer has progressed despite all currently approved treatment regimens. This is the second new drug approved by the FDA recently after a…  Read More